INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 415m ago
HOUSE PTR15m ago
SEC 13F15m ago
ROBINHOOD CHAIN15m ago
SEC FORM 4/Open-market saleVerified data

Stout Jay S sold IMVT

Chief Technology Officer · Immunovant, Inc. · Common Stock

Side
SELL
Value
$75K
Shares
2,595
Price
$28.94
Executed
Oct 21, 2026
Disclosed
Oct 23, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Oct 21 executedOct 23, 2026 disclosed

IMVT · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
32/ 100 · ELEVATED
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+4 / 25

    $75K reported value · 1.3% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+1 / 15

    Routine: 10 prior trades recorded in this security

  • Frequency & clustering+15 / 15

    3 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · IMVT

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    25
    GT
    Girao TiagoChief Financial Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$188K
    6,606 sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    24
    VC
    Van Tuyl ChristopherChief Legal Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$43K
    1,327 sh
    		Oct 7, 2026Oct 9, 2026
    traded Oct 7, 2026
    		+2dSEC FORM 4

    Evidence

    27
    GM
    Gloria MelanieChief Operating Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$72K
    2,241 sh
    		Oct 7, 2026Oct 9, 2026
    traded Oct 7, 2026
    		+2dSEC FORM 4

    Evidence

    27
    SS
    Stout Jay SChief Technology Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$71K
    2,213 sh
    		Oct 7, 2026Oct 9, 2026
    traded Oct 7, 2026
    		+2dSEC FORM 4

    Evidence

    27
    SS
    Stout Jay SChief Technology Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$51K
    1,596 sh
    		Oct 7, 2026Oct 9, 2026
    traded Oct 7, 2026
    		+2dSEC FORM 4

    Evidence

    27
    VC
    Van Tuyl ChristopherChief Legal Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$103K
    2,846 sh
    		Sep 23, 2026Sep 25, 2026
    traded Sep 23, 2026
    		+2dSEC FORM 4

    Evidence

    0
    PA
    Pande AtulDirector
    IMVTImmunovant, Inc.
    Option exercise · 10b5-1 plan
    		M$13K
    1,500 sh
    		Aug 28, 2026Aug 28, 2026
    traded Aug 28, 2026
    		+0dSEC FORM 4

    Evidence

    0
    PA
    Pande AtulDirector
    IMVTImmunovant, Inc.
    Option exercise · 10b5-1 plan
    		M—
    1,500 sh
    		Aug 28, 2026Aug 28, 2026
    traded Aug 28, 2026
    		+0dSEC FORM 4

    Evidence

    9
    PA
    Pande AtulDirector
    IMVTImmunovant, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$65K
    1,500 sh
    		Aug 28, 2026Aug 28, 2026
    traded Aug 28, 2026
    		+0dSEC FORM 4

    Evidence

    25
    GM
    Gloria MelanieChief Operating Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$135K
    3,056 sh
    		Aug 20, 2026Aug 21, 2026
    traded Aug 20, 2026
    		+1dSEC FORM 4

    Evidence

    8
    GT
    Girao TiagoChief Financial Officer
    IMVTImmunovant, Inc.
    Option exercise
    		M$159K
    10.0K sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    35
    SS
    Stout Jay SChief Technology Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$262K
    6,723 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    15
    VC
    Van Tuyl ChristopherChief Legal Officer
    IMVTImmunovant, Inc.
    Option exercise
    		M$271K
    17.8K sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    35
    VC
    Van Tuyl ChristopherChief Legal Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$111K
    2,842 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    13
    VC
    Van Tuyl ChristopherChief Legal Officer
    IMVTImmunovant, Inc.
    Option exercise
    		M—
    17.8K sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    5
    GT
    Girao TiagoChief Financial Officer
    IMVTImmunovant, Inc.
    Option exercise
    		M—
    10.0K sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    0
    PA
    Pande AtulDirector
    IMVTImmunovant, Inc.
    Option exercise · 10b5-1 plan
    		M$13K
    1,500 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    23
    PA
    Pande AtulDirector
    IMVTImmunovant, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$57K
    1,500 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    0
    PA
    Pande AtulDirector
    IMVTImmunovant, Inc.
    Option exercise · 10b5-1 plan
    		M—
    1,500 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    38
    GT
    Girao TiagoChief Financial Officer
    IMVTImmunovant, Inc.
    Open-market sale
    		SELL$385K
    10.0K sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001764013-26-000114
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 21, 2026
    Published
    Oct 23, 2026
    Ingested by INSIDER
    Nov 5, 02:09 UTC
    Last re-read
    Nov 5, 02:09 UTC

    Extracted facts

    Filer
    Stout Jay S
    Role
    Chief Technology Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Immunovant, Inc.
    Ticker
    IMVT
    Shares
    2,595
    Price per share
    $28.94
    Value
    $75,099
    Execution date (reported)
    Oct 21, 2026
    Owned after transaction
    198.9K shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 2,595
    • Price: $28.94

    = $75,099

    What this establishes

    Stout Jay S filed this Form 4 reporting a open-market sale of IMVT on Oct 21, 2026. It became public on Oct 23, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Technology Officer
    Stout Jay Scik:0001702969
    Issuer
    Immunovant, Inc.cik:0001764013

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.